目的 評價恩格列凈治療2型糖尿病的安全性。方法 檢索PubMed、Embase、CENTRAL，中國學(xué)術(shù)期刊全文數(shù)據(jù)庫（CNKI）、中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫（CBM）和萬方等數(shù)據(jù)庫，檢索時限從建庫至2018年3月，納入有關(guān)的隨機(jī)對照試驗（RCTs），用Stata 14軟件完成Meta-分析。結(jié)果 共納入10篇文獻(xiàn)，6 618例患者。Meta-分析結(jié)果發(fā)現(xiàn)：治療末期，恩格列凈生殖器感染發(fā)生人數(shù)明顯多于對照組，差異有統(tǒng)計學(xué)意義[OR=3.65，95% CI（2.55，5.23）]；恩格列凈組尿路感染發(fā)生人數(shù)與對照組相當(dāng)，差異無統(tǒng)計學(xué)意義[OR=0.95，95% CI（0.82，1.11）]；恩格列凈組與對照組低血糖發(fā)生人數(shù)相當(dāng)，差異無統(tǒng)計學(xué)意義[OR=1.05，95% CI（0.82，1.36）]；恩格列凈組與對照組骨折發(fā)生人數(shù)相當(dāng)，差異無統(tǒng)計學(xué)意義[OR=1.143，95% CI（0.59，2.216）]。結(jié)論 恩格列凈治療2型糖尿病僅增加生殖器感染風(fēng)險，不會增加尿路感染、低血糖、骨折發(fā)生率，安全性較好。

Objective To assess the safety of empaliflozin for T2DM patients. Methods Databases including PubMed, Embase, CENTRAL, CBM, CNKI and Wanfang Data were searched to collect randomized controlled trials(RCTs) about safety of empaliflozin for T2DM patients from inception to March 2018, conventional Meta-analysis were performed by Stata 14. Results Ten literature involving 6 618 patients were eligible for Meta-analysis. Meta-analysis showed that at the end of trials, empagliflozin obviously increased the patients of genital infections, the difference was significant[OR=3.65, 95% CI(2.55, 5.23)]; empagliflozin were comparable to control group in the number of patients who had urinary tract infections, hypoglycemia and bone fracture, there were no significant differences[OR=0.95, 95% CI(0.82, 1.11); OR=1.05, 95% CI (0.82, 1.36); OR=1.143, 95% CI (0.59, 2.216)]. Conclusion Empagliflozin only increased the risk of genital infections, excpet for urinary tract infections, hypoglycemia and bone fracture, had good safety.